{
    "clinical_study": {
        "@rank": "166662", 
        "arm_group": {
            "arm_group_label": "Adults who diagosed ANCA-vasculitis", 
            "description": "Patients with Wegener's granulomatosis or microscopic polyangiitis were eligible to participate in the study if they had\nPositive serum assays for proteinase 3-ANCA or myeloperoxidase-ANCA\nmanifestations of severe disease,11 and a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) of 3 or more (scores range from 0 to 63, with higher scores indicating more active disease)"
        }, 
        "biospec_descr": {
            "textblock": "serum lymphocytes urine"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The purpose of this study is to observe the clinical manifestation, Lab findings including\n      chest CT scans, pathological findings and outcomes in chinese patients with pulminary\n      vasculitis."
        }, 
        "brief_title": "Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "ANCA-associated Vasculitis", 
            "Granulomatosis With Polyangiitis", 
            "Microscopic Polyangiitis", 
            "EosinphilicGranulomatosis With Polyangiitis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Vasculitis", 
                "Wegener Granulomatosis", 
                "Systemic Vasculitis", 
                "Microscopic Polyangiitis", 
                "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Presentation of patient with suspected vasculitis\n\n        1. Established diagnosis Clinical findings Laboratory workup Tissue biopsy Angiogram where\n           appropriate\n\n        2. Evaluating respiratory system Chest HRCT Pulmonary function test Bronchoscopy\n           exam(BALF, TBB) Lung biopsy(needle biopsy, VAST)\n\n        3. screening underlying damage to other system Paranasal sinus, vision & audition Nervous\n           system Kidney Gastrointestinal tract Heart & vessel Skin Hematology Muscle, bone &\n           joint\n\n        4. Treatment\n\n        5. Prognosis\n\n      Evaluation\n\n        1. Study visits occurred at baseline; at weeks 4; and at 2, 4, 6,12,18,24,30 months.\n\n        2. Disease activity was measured on the basis of the BVAS/WG and the physician's global\n           assessment.\n\n        3. Damage related to disease or treatment was scored according to the Vasculitis Damage\n           Index (scores for this index range from 0 to 64, with higher scores in- dicating more\n           severe damage).\n\n        4. Health related quality of life was scored with the use of the Med- ical Outcomes Study\n           36-Item Short-Form Health Survey (SF-36).Scores on this scale range from 0 to 100, with\n           higher scores indicating better health.\n\n        5. Serial serum samples were tested for proteinase 3-ANCA and myeloperoxidase-ANCA by\n           means of a direct enzyme-linked immunosorbent assay (ELISA)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and Females\n\n          -  Aged from 18-75 years with informed consent\n\n          -  Patients with ANCA-vasculitis\n\n               1. Wegener's granulomatosis, microscopic polyangiitis or CSS\n\n               2. positive serum assays for proteinase 3-ANCA or myeloperoxidase-ANCA\n\n               3. manifestations of activity disease, and Birmingham Vasculitis Activity Score for\n                  Wegener's Granulomatosis (BVAS/WG) of 3 or more (scores range from 0 to 63, with\n                  higher scores indicating more active disease)\n\n        Exclusion Criteria:\n\n          -  Females planning to bear a child recently or with childbearing potential\n\n          -  Secondary vasculitis, cancer,infective disease or drug induced vasculitis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients who newly diagnosed  ANCA-vasculitis"
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02126098", 
            "org_study_id": "PUMCH-PULMONARY DISEASES", 
            "secondary_id": "2011BA11B17"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ANCA-associated vasculitis", 
            "Granulomatosis with polyangiitis", 
            "Microscopic polyangiitis", 
            "Wegner's granulomatosis", 
            "Eosinphilic granulomatosis with polyangiitis"
        ], 
        "lastchanged_date": "April 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100730"
                }, 
                "name": "Peking Union Medical College Hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "Cohort Study of Chinese Patients With Pulmonary Vasculitis", 
        "other_outcome": {
            "description": "deaths (from all causes)\nmalignant conditions\ngrade 2 or higher leukopenia or thrombocytopenia\ngrade 3 or higher infections\ndrug induced cystitis\nvenous thromboembolic events\nstroke\nhospitalizations", 
            "measure": "Adverse events", 
            "safety_issue": "No", 
            "time_frame": "during the period of observation (30months)"
        }, 
        "overall_contact": {
            "email": "juhong_shi@hotmail.com", 
            "last_name": "Juhong Shi, M.D", 
            "phone": "+861069155028"
        }, 
        "overall_contact_backup": {
            "email": "qinlingpumch@126.com", 
            "last_name": "Ling Qin, M.D", 
            "phone": "+861069155028"
        }, 
        "overall_official": {
            "affiliation": "Peking Union Medical College Hospital", 
            "last_name": "Juhong Shi, M.D", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "BVAS/WG of 0 and successful completion of the prednisone taper at 6 months.", 
            "measure": "Completely Remission", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02126098"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Disease flare\nan increase in the BVAS/WG of 1 point or more.\nPatients were classified as having early treatment failure if at 1 month their BVAS/WG had not decreased by at least 1 point or a new manifestation of disease had emerged.", 
            "measure": "Disease flare", 
            "safety_issue": "No", 
            "time_frame": "during the period of observation(30months)"
        }, 
        "source": "Peking Union Medical College Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Peking Union Medical College Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "30 Months", 
        "verification_date": "April 2014"
    }
}